ClinicalTrials.gg
RecruitingNCT06561932TLC-AUUpdated Oct 14, 2026

A Feasibility Study Implant of the WiSE® CRT System With an Intracardiac Pacemaker to Achieve Totally Leadless CRT

An interventional study of WiSE CRT System in Heart Failure, sponsored by EBR Systems, Inc.. Recruiting at 4 sites in Australia. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by EBR Systems, Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Oct 14, 2026Site recruiting status changedStudy contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 167 studies in Heart Failure with a site in Australia — 25 open to participants now, 41 under way, 9 of them phase 3. Heart Failure · Australia.

Planned enrollment
110th of 135
40 · median 350
Started
2025
with 9 others
No phase
57 of 167
14 open now
Primary completion
2027-04
later than 20 of 40 live
Registered
154th of 167
by date

Among the 167 studies in Heart Failure with a site in Australia, this one is the 110th largest by planned enrollment of the 135 interventional ones that give a count, is one of 10 that started in 2025, is one of 57 with no phase, reaches primary completion later than 20 of the 40 other live ones, and was the 154th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

25 of the 167 studies in Heart Failure with a site in Australia are open now. Recruiting first, the newest first:

19 more — sign in →

All 25 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 167 studies in Heart Failure with a site in Australia, or all of them as a file.
02

Study summary

Assess the safety and efficacy of the co-implantation of the WiSE CRT System with an intracardiac pacemaker to provide totally leadless CRT.

Read the detailed description

The WiSE CRT System is an implantable cardiac system to provide left ventricular (LV) pacing stimulation in conjunction with a co-implanted system that provides right ventricular (RV) stimulation. In combination, the devices deliver biventricular (BiV) pacing.

Single-arm, prospective, multicenter, observational study.

03

Conditions studied

  • Heart Failure

Browse trials for

04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with a class I or IIa (1) or (2) indication for implantation of a CRT device according to current available guidelines 1,2,4 (with additional QRS criteria on Class IIa (1)):

    • Class I: II, III, IV, EF ≤ 35%, LBBB, QRS ≥ 150 ms
    • Class IIa (1): NYHA II, III, IV, EF ≤ 35%, LBBB, QRS ≥ 130 to \< 150 ms
    • Class IIa (2): NYHA II, III, IV, EF ≤ 35%, non-LBBB, QRS ≥ 150 ms
  • Patient or legally authorized representative can provide written authorization and/or consent per institution requirements
  • Male or Female, aged 22 years or above
  • Meets criteria for one of the two patient groups

    • Group A: De novo totally leadless CRT implant in whom the physician believes a totally leadless approach would be beneficial (e.g., wish to avoid lifelong transvenous lead implant, anatomical constraints, history of device infection).

      • Patients with symptomatic AF and an uncontrolled heart rate who are candidates for AV node ablation (irrespective of QRS duration and ), and in whom the physician believes a leadless pacing approach would be beneficial.
      • Patients with high degree AV block who have an indication for permanent pacing (with a LVEF ≤ 50%), are expected to require ventricular pacing more than 40% of the time, and in whom the physician believes a leadless approach would be beneficial.
    • Group B: Upgrade chronic intracardiac pacemaker to CRT

      • Patients with existing intracardiac pacemakers with greater than 20% RV pacing, who have developed symptomatic HF.

Exclusion criteria

Exclusion Criteria:

  • Patient who is or is expected to be inaccessible for follow-up visits
  • Female participant who is pregnant, lactating, or planning pregnancy during the course of the study
  • Inability to comply with the study follow-up or other study requirements
  • History of chronic alcohol/ drug abuse and currently using alcohol/ drugs
  • Non-ambulatory (or unstable) class 4
  • less than 12 months
  • Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.
  • Patient who is enrolled in another clinical study that could confound the results of this study (Note: patients enrolled in complementary study are eligible for enrolment)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Single-arm, prospective, multicenter, observational study.

    .WiSE System therapy ON with Guideline Directed Medical Therapy

    Device: WiSE CRT System

Interventions

  • DeviceWiSE CRT System

    The WiSE CRT System is an implantable cardiac system to provide left ventricular (LV) pacing stimulation in conjunction with a co-implanted system that provides right ventricular (RV) stimulation. In combination, the devices deliver biventricular (BiV) pacing.

06

What researchers measure

Primary outcomes

  1. Incidence of Device and procedure related complications.

    Primary Safety

    Time frame: 1 month and 6 months

  2. Bi-Ventricular capture on 12 lead EKG

    Performance

    Time frame: 1 month and 6 months

Secondary outcomes

  1. Change in ejection fraction (EF) from Baseline

    Secondary efficacy 1

    Time frame: 6 months

  2. Change in in left ventricular end systolic volume (LVESV)

    Secondary efficacy 2

    Time frame: 6 months

  3. Change in NYHA class

    Secondary efficacy 3

    Time frame: 6 months

  4. Change in Six-minute walk test

    Secondary efficacy 4

    Time frame: 6 months

07

Study locations

4 of 4 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Apr 2027, 15 months after the start.

Of 236 industry-sponsored interventional studies with no phase under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 61. This study's planned 15 months is below that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2024
First posted
Aug 20, 2024
StartActual
Dec 18, 2025
Primary completionEst.
Apr 1, 2027
CompletionEst.
Apr 1, 2027
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites changed recruiting status (3 now recruiting)
Show 3 sites
  • Patients of Sunshine Coast University Hospital · Birtinya, AustraliaNot yet recruiting→Recruiting
  • Royal Brisbane and Women's Hospital · Herston, AustraliaNot yet recruiting→Recruiting
  • Patients of Gold Coast University Hospital · Southport, AustraliaNot yet recruiting→Recruiting
Oct 14, 2026
Contact
Study contact changed: c•••@ebrsystemsinc.com · •••3675→c•••@ebrwise.com · •••1906. See the current contact
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    3 sites changed recruiting status (3 now recruiting)
    Show 3 sites
    • Patients of Sunshine Coast University Hospital · Birtinya, AustraliaNot yet recruiting→Recruiting
    • Royal Brisbane and Women's Hospital · Herston, AustraliaNot yet recruiting→Recruiting
    • Patients of Gold Coast University Hospital · Southport, AustraliaNot yet recruiting→Recruiting
    Contact Study contact changed: c•••@ebrsystemsinc.com · •••3675→c•••@ebrwise.com · •••1906. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06561932
Lead sponsor
EBR Systems, Inc.
Responsible party
Sponsor
First posted
Aug 20, 2024
Start date
Dec 18, 2025
Primary completion
Apr 1, 2027 (estimated)
Completion
Apr 1, 2027 (estimated)
Last update
Oct 14, 2026

Study contacts

Jamie Burke
Contact
clinical@ebrwise.com
408-720-1906
Paul Gould, Prof
principal investigator · Princess Alexandra Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion